Recursion Pharmaceuticals (RXRX) Financial Statements & Analysis

Recursion Pharmaceuticals (RXRX) Income Statement

Recursion Pharmaceuticals reported revenue of $74.26M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 26.2% from $58.84M a year earlier. Recursion Pharmaceuticals posted a net loss of $644.76M, compared with a net loss of $463.66M a year earlier. Gross margin was 4.4% and operating margin -872.8%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $7.67M, down 60.1% from the same quarter a year earlier.

Recursion Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Recursion Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	74.26	58.84	43.88	39.68	10.00	3.41	1.71
Cost of Revenue	70.95	45.24	42.59	48.28	0.00	0.00	45.81
Gross Profit	3.30	13.60	1.29	-8.59	10.00	3.41	-44.10
Operating Expenses
Research & Development	475.27	314.42	241.23	155.70	135.27	63.32	45.81
Selling, General & Administrative	176.59	178.18	110.82	81.60	57.68	25.26	18.95
Operating Expenses	651.44	492.61	351.35	237.13	192.78	88.03	64.15
Operating Income	-648.13	-479.00	-350.06	-245.73	-182.78	-84.62	-62.44
Other Income/Expense
Interest Income	22.79	15.76	19.12	6.25	0.07	0.34	1.74
Interest Expense	1.81	1.57	0.10	0.06	2.95	1.36	0.64
Other Income/Expense	-17.74	14.22	17.93	6.25	-3.70	-2.39	0.56
Income
Income Before Tax	-644.90	-464.79	-332.13	-239.48	-186.48	-87.01	-61.88
Income Tax Expense	-0.14	-1.13	-4.06	0.00	0.00	0.00	0.00
Net Income	-644.76	-463.66	-328.07	-239.48	-186.48	-87.01	-62.53
Net Income - Continuous Operations	-644.76	-463.66	-328.07	-239.48	-186.48	-87.01	-62.53
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-559.38	-426.72	-307.63	-227.67	-175.12	-81.70	-58.34
EBIT	-643.09	-479.00	-350.06	-245.73	-183.53	-84.62	-
Depreciation & Amortization	83.70	36.49	24.40	11.76	8.41	3.94	3.54
Earnings Per Share
Basic EPS	-1.00	-2.00	-2.00	-1.00	-1.00	-1.00	-
Diluted EPS	-1.00	-2.00	-2.00	-1.00	-1.00	-1.00	-
Basic Shares Outstanding	447.45	274.21	207.85	175.54	170.27	165.79	165.79
Diluted Shares Outstanding	447.45	274.21	207.85	175.54	170.27	165.79	165.79

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Recursion Pharmaceuticals Financial Statements

What was Recursion Pharmaceuticals's revenue in fiscal 2025?

Recursion Pharmaceuticals reported revenue of $74.26M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 26.2% from $58.84M a year earlier.

Is Recursion Pharmaceuticals profitable?

No. Recursion Pharmaceuticals reported a net loss of $644.76M in fiscal 2025. In fiscal 2024 it lost $463.66M.

What is Recursion Pharmaceuticals's operating margin?

Recursion Pharmaceuticals's operating income was −$648.13M on revenue of $74.26M in fiscal 2025, an operating margin of -872.8%, compared with -814.1% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition